Skip to main content
. 2022 Oct 26;16(11):18232–18243. doi: 10.1021/acsnano.2c05710

Figure 6.

Figure 6

(A) Schematic presentation of the chemodynamic treatment of an MDA-MB-231 cancer cell using targeting AS1411 aptamer-functionalized pA-AuNPs, a ROS-generating nanozyme. (B) Temporal imaging of ROS intermediates generated in (a) epithelial MCF-10A breast cells treated with pA-AuNPs (lacking the AS1411 aptamer), (b) epithelial MCF-10A breast cells treated with the AS1411 aptamer conjugated to the pA-AuNPs, (c) MDA-MB-231 breast cancer cells treated with the pA-AuNPs (lacking the AS1411 aptamer units), and (d) MDA-MB-231 breast cancer cells treated with the AS1411 aptamer conjugated to the pA-AuNPs. In all experiments, cells were treated with 5 nM of the respective NPs. (C) Time-dependent integrated fluorescence intensities of ROS products generated by (a) MCF-10A cells treated with pA-AuNPs, (b) MCF-10A cells treated with AS1411/pA AuNPs conjugate, (c) MDA-MB-231 cancer cells treated with pA-AuNPs, and (d) MDA-MB-231 cancer cells treated with AS1411/pA-AuNPs conjugate. Fluorescence was generated by staining the respective cells with di(acetoxymethyl ester)-6-carboxy-2′,7′-dichlorodihydrofluorescein diacetate (C-DCDHF-DA). Error bars derived by analyzing N = 4 frames of cells. (D) Cell viability of MCF-10A epithelial breast cells (green columns) and MDA-MB-231 breast cancer cells (red columns) treated with (a) control system consisting of untreated cells; columns (b1), (b2), and (b3) correspond to treatment of the cells for 2 days with pA-AuNPs (non-aptamer conjugates) using doses corresponding to 0.9 nM, 1.2 nM, and 1.5 nM, respectively, and columns (c1), (c2), and (c3) correspond to cells treated with the AS1411/pA-AuNPs conjugates using doses corresponding to 0.9 nM, 1.2 nM, and 1.5 nM.